Cord Blood News Volume 8.14 | Apr 14 2016

Dexmedetomidine Inhibits Maturation and Function of Human Cord Blood-Derived Dendritic Cells by Interfering with Synthesis and Secretion of IL-12 and IL-23
Human dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs) were obtained from human cord blood mononuclear cells by density gradient centrifugation. Researchers investigated the effects and underlying mechanism of dexmedetomidine on cultured human DCs. [PLoS One] Full Article

The Combined Effect of PDX1, Epidermal Growth Factor and Poly-L-Ornithine on Human Amnion Epithelial Cells’ Differentiation
Scientists chose to drive pancreatic development in human amnion epithelial cells by inducing endogenous PDX1 expression. Further, they investigated the role of epidermal growth factor and poly-L-ornithine on this differentiation process. [BMC Dev Biol] Full Article

Intratracheal Transplantation of Mesenchymal Stem Cells Simultaneously Attenuates Both Lung and Brain Injuries in Hyperoxic Newborn Rats
Scientists investigated whether attenuation of hyperoxic lung injury with intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells could simultaneously mitigate brain damage in neonatal rats. [Pediatr Res] Abstract

Electrophysiology, Immunophenotype, and Gene Expression Characterization of Senescent and Cryopreserved Human Amniotic Fluid Stem Cells
The authors characterized human amniotic fluid stem cells in senescent cultures (6 weeks) versus cryopreserved cells using whole-cell patch-clamp, immunophenotyping, and differential gene expression profiling for senescence genes. [J Physiol Sci] Abstract

Polymer Mesh Scaffold Combined with Cell-Derived ECM for Osteogenesis of Human Mesenchymal Stem Cells
Investigators utilized a PLGA/PLA mesh scaffold, coated with cell-derived extracellular matrix and assessed its potential as an osteogenic microenvironment for human umbilical cord blood-derived mesenchymal stem cells. [Biomater Res] Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.

FDA Approves New Drug for Chronic Lymphocytic Leukemia in Patients with a Specific Chromosomal Abnormality
The U.S. Food and Drug Administration (FDA) approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 protein, which supports cancer cell growth and is overexpressed in many patients with CLL. [U.S. Food and Drug Administration] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells. Watch the video.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Principal Investigator – Stem Cell Biology and Regeneration Medicine (Guangzhou Women and Children’s Medical Center)

Engineering Project Lead (Cytonome)

Postdoctoral Scientist – Hematological Malignancies (Max Delbruck Center for Molecular Medicine in the Helmholtz Association)

Postdoctoral Research Associate – Pediatric Acute Lymphoblastic Leukemia (University of Pittsburgh)

Postdoctoral Research Associate – Blood Stem cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Research Fellow – Erythropoiesis (New York Blood Center)

Postdoctoral Fellow – Stem Cell Biology and Regenerative Medicine (Cleveland Clinic)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.